Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Lithium Americas Corp (LAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Lithium Americas Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Lithium Americas Corp trades at $3.16 (market cap $1.11B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 7.2× Lithium Americas Corp's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals.
| BIO | LAC | |
|---|---|---|
Market Cap | $8.04B | $1.11B |
Sector | Health | Basic Materials |
52-Week High | $339.75 | $10.05 |
52-Week Low | $241.71 | $2.55 |
Enterprise Value | $7.85B | $1.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Lithium Americas (LAC) trades at $3.14, down 5.42% on the day, reflecting ongoing market pressure despite recent earnings beats. The stock shows mixed signals with bearish technical indicators but bullish oscillators suggesting potential oversold conditions. Fundamentally, the company remains in development phase with negative profitability metrics (ROE -11.35%, net loss $122M in 2025) but maintains analyst support for its Thacker Pass lithium project development.
LAC presents a high-risk, high-reward opportunity with significant execution risk on its capital-intensive lithium project. While analyst consensus targets $6.25 (99% upside), investors face dilution risk from ongoing financing needs and operational challenges. The stock's appeal hinges on successful project development and lithium market recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
